2011
DOI: 10.4155/cli.11.143
|View full text |Cite
|
Sign up to set email alerts
|

New and emerging therapies for gout

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2014
2014
2023
2023

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 69 publications
0
2
0
Order By: Relevance
“…34 Given these assertions, it is tempting to consider whether the beneficial effects of the anti-fibrotic agent, tranilast, in diabetic nephropathy, 35,36 may also be partly a consequence of its uricosuric action. 37…”
Section: Uric Acid Uric Acid and Cardiorenal Diseasementioning
confidence: 99%
“…34 Given these assertions, it is tempting to consider whether the beneficial effects of the anti-fibrotic agent, tranilast, in diabetic nephropathy, 35,36 may also be partly a consequence of its uricosuric action. 37…”
Section: Uric Acid Uric Acid and Cardiorenal Diseasementioning
confidence: 99%
“…Our paper is a hybrid: not a review, but it references some academic literature; not a research study, but with development of hypotheses to be tested in sound research designs; not a case study, but with 13 cases presented from which theory can be proposed; not a new approach to clinical assessment or treatment, but with recommendations to consider until empirical research based on its ideas can inform practice. We expand on our version of a sequential, cross-sectional longitudinal case methodology in the accompanying paper (Crittenden, 2023).…”
Section: Methodological Considerationsmentioning
confidence: 99%